Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma

Zhou,Fei; Mu,Yin‑Dong; Liang,Jun; Liu,Zhi‑Xin; Chen,Hong‑Sheng; Zhang,Ji‑Fei

doi:10.3892/ol.2013.1723

Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma

Authors:
- Fei Zhou
- Yin‑Dong Mu
- Jun Liang
- Zhi‑Xin Liu
- Hong‑Sheng Chen
- Ji‑Fei Zhang
View Affiliations

Affiliations: Department of Anorectal Surgery, Qiqihar Traditional Chinese Medicine Hospital, Qiqihar, Heilongjiang 161000, P.R. China, Department of Histology and Embryology, Mudanjiang Medical College, Mudanjiang, Heilongjiang 157000, P.R. China, Treatment Center of Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: December 2, 2013 https://doi.org/10.3892/ol.2013.1723
Pages: 507-512

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The identification of cancer stem cells (CSCs) has improved the understanding of tumor occurrence and development. According to CSC theory, colorectal carcinoma (CRC) may be derived from these few cells. Thus, markers for CSCs may lead to the identification of CSCs and investigation of the correlation with various clinicopathological features and survival time in human CRC patients. Aldehyde dehydrogenase 1 (ALDH1) and CD133 (also known as Prominin‑1 or AC133) were involved in the current study. The aim of the present study was to identify CSCs through markers of CSCs and to explore the value of the CSC markers, ALDH1 and CD133, in human CRC. The correlation between ALDH1 and CD133 protein expression and the various clinicopathological parameters were investigated through immunohistochemistry (IHC). In addition, the Kaplan‑Meier method was used to estimate patients' overall survival. Correlation of the survival differences between ALDH1‑ or CD133‑positive expression and negative controls was analyzed by the log‑rank test. Furthermore, the correlation between the expression of ALDH1 and CD133 was assessed by Spearman's rank correlation. A marked correlation between the differentiation degree and expression of ALDH1 in tumor cells was demonstrated, but not with CD133 expression. In addition, it was demonstrated that low‑stage tumors exhibit a higher expression of ALDH1 or CD133 staining compared with high‑stage tumors. Meanwhile, CD133 expression was associated with lymph node metastasis‑positive cases, but ALDH1 expression was not. Furthermore, compared with negative cases, ALDH1‑positive patients exhibited a poor prognosis. However, no significant difference was identified between CD133‑positive and ‑negative cases in terms of survival time. Overall, the results of the present study indicated that ALDH1 and CD133 may serve as useful markers of CSC to predict disease prognosis and clinicopathological characteristics of human CRC.

View Figures

View References

1	Center MM, Jemal A and Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 18:1688–1694. 2009. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
3	Peppone LJ, Mahoney MC, Cummings KM, Michalek AM, Reid ME, Moysich KB and Hyland A: Colorectal cancer earlier in those exposed to tobacco smoke: implication for screening. J Cancer Res Clin Oncol. 134:743–751. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hamburger AW and Salmon SE: Primary bioassay of human tumor stem cells. Science. 197:461–463. 1977. View Article : Google Scholar : PubMed/NCBI
5	Boman BM and Wicha MS: Cancer stem cells: a step toward the cure. J Clin Oncol. 26:2795–2799. 2008. View Article : Google Scholar : PubMed/NCBI
6	Abdul Khalek FJ, Gallicano GI and Mishra L: Colon cancer stem cells. Gastrointest Cancer Res. Nov;(Suppl 1): S16–S23. 2010.
7	Sophos NA and Vasiliou V: Aldehyde dehydrogenase gene superfamily: the 2002 update. Chem Biol Interact. 143–144:5–22. 2003.PubMed/NCBI
8	Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 69:3382–3389. 2009. View Article : Google Scholar
9	Patel M, Lu L, Zander DS, Sreerama L, Coco D and Moreb JS: ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 59:340–349. 2008. View Article : Google Scholar
10	Nogami T, Shien T, Tanaka T, Nishiyama K, Mizoo T, Iwamto T, et al: Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1–3 lymph node metastases. Breast Cancer. Mar 10–2012.(Epub ahead of print).
11	Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, et al: The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 275:5512–5520. 2000. View Article : Google Scholar
12	Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al: Identification of human brain tumor initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
13	Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
14	Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI
15	Hermann PC, Huber SI, Herrler T, Aicher A, Ellwart JW, Guba M, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007. View Article : Google Scholar : PubMed/NCBI
16	Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
17	O’Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature. 445:106–110. 2007.PubMed/NCBI
18	Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
19	Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Lovino F, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 1:389–402. 2007. View Article : Google Scholar : PubMed/NCBI
20	Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, et al: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 15:638–648. 2008. View Article : Google Scholar : PubMed/NCBI
21	Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 99:1285–1289. 2008. View Article : Google Scholar : PubMed/NCBI
22	Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ and Boman BM: Evidence that APC regulates surviving expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 61:8664–8667. 2001.
23	Boman BM, Walters R, Fields JZ, Kovatich AJ, Zhang T, Isenberg GA, et al: Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population. Am J Pathol. 165:1489–1498. 2004. View Article : Google Scholar
24	Horst D, Sheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T and Jung A: The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 219:427–434. 2009. View Article : Google Scholar
25	Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, et al: CD133 expression is not restricted to stem cells and both CD133⁺ and CD133⁻ metastatic colon cancer cells initiate tumors. J Clin Invest. 118:2111–2120. 2008.PubMed/NCBI